Sicomed withdraws product

Sicomed Bucharest has decided to withdraw from the market a drug called Mivastin, used for treating cardiovascular conditions, due to esthetical issues with this product. “The Mivastin drug is being withdrawn from the market because the internal stability studies showed changes in the aspect of the pills in some cases. Although it is just an esthetical matter, the quality standards of the company require this decision to be adopted. Mivastin may be reintroduced on the market in the future,” stated Klaas Postema, Sicomed”s executive chairman. The company has already begun procedures to withdraw the drug. The market of simvastatins that comprises Mivastin, amounted to 10 million euros in the first nine months of the year and Sicomed accounts for about 25% of the market with this product. Sicomed”s Mivastin sales in the first nine months of this year stood at 2.3 million euros, according to market research company CEGEDIM. ZF